Literature DB >> 16760525

Experimental yellow fever virus infection in the golden hamster (Mesocricetus auratus) III. Clinical laboratory values.

Elena Sbrana1, Shu-Yuan Xiao, Vsevolod L Popov, Patrick C Newman, Robert B Tesh.   

Abstract

Using a recently described hamster model of yellow fever (YF), we compared the hematologic and clinical chemistry changes that occur in blood with the histopathologic alternations observed in liver and other organs. Inflammatory foci and necroapoptotic hepatocytes were first observed in the liver three days after YF infection. This was accompanied by a rapid increase in serum transaminase and bilirubin values, elevation of prothrombin times, thrombocytopenia, and leukocytosis. Maximum liver pathology was observed on the sixth and seventh days post-infection; this corresponded to the peak alternations in clinical chemistry and hematologic values. In surviving hamsters, regenerating hepatocytes began to appear on the eighth day post-infection; this was accompanied by a corresponding return to baseline levels of most of the aforementioned clinical laboratory values. The histopathologic and clinical laboratory findings in the hamster model were very similar to those observed in severe human cases of YF. These results provide further validation of the utility of the hamster model for studying the pathogenesis and treatment of YF.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16760525

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  21 in total

1.  1,25-dihydroxyvitamin D3 treatment shrinks uterine leiomyoma tumors in the Eker rat model.

Authors:  Sunil K Halder; Chakradhari Sharan; Ayman Al-Hendy
Journal:  Biol Reprod       Date:  2012-04-19       Impact factor: 4.285

2.  BCX4430, a novel nucleoside analog, effectively treats yellow fever in a Hamster model.

Authors:  Justin G Julander; Shanta Bantia; Brian R Taubenheim; Dena M Minning; Pravin Kotian; John D Morrey; Donald F Smee; William P Sheridan; Yarlagadda S Babu
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

3.  A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse model.

Authors:  Brett A Thibodeaux; Nina C Garbino; Nathan M Liss; Joseph Piper; Jacob J Schlesinger; Carol D Blair; John T Roehrig
Journal:  Antiviral Res       Date:  2012-02-15       Impact factor: 5.970

Review 4.  Experimental therapies for yellow fever.

Authors:  Justin G Julander
Journal:  Antiviral Res       Date:  2012-12-10       Impact factor: 5.970

Review 5.  An Overview of Animal Models for Arthropod-Borne Viruses.

Authors:  Erin S Reynolds; Charles E Hart; Meghan E Hermance; Douglas L Brining; Saravanan Thangamani
Journal:  Comp Med       Date:  2017-06-01       Impact factor: 0.982

6.  Comparison of the inhibitory effects of interferon alfacon-1 and ribavirin on yellow fever virus infection in a hamster model.

Authors:  Justin G Julander; John D Morrey; Lawrence M Blatt; Kristiina Shafer; Robert W Sidwell
Journal:  Antiviral Res       Date:  2006-09-22       Impact factor: 5.970

7.  Humanized monoclonal antibody 2C9-cIgG has enhanced efficacy for yellow fever prophylaxis and therapy in an immunocompetent animal model.

Authors:  Justin G Julander; Brett A Thibodeaux; John D Morrey; John T Roehrig; Carol D Blair
Journal:  Antiviral Res       Date:  2014-01-03       Impact factor: 5.970

8.  Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.

Authors:  Justin G Julander; Kristiina Shafer; Donald F Smee; John D Morrey; Yousuke Furuta
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

9.  Assessing changes in vascular permeability in a hamster model of viral hemorrhagic fever.

Authors:  Brian B Gowen; Justin G Julander; Nyall R London; Min-Hui Wong; Deanna Larson; John D Morrey; Dean Y Li; Mike Bray
Journal:  Virol J       Date:  2010-09-16       Impact factor: 4.099

10.  A mouse model for studying viscerotropic disease caused by yellow fever virus infection.

Authors:  Kathryn C Meier; Christina L Gardner; Mikhail V Khoretonenko; William B Klimstra; Kate D Ryman
Journal:  PLoS Pathog       Date:  2009-10-09       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.